HC Wainwright Begins Coverage on Phio Pharmaceuticals (NASDAQ:PHIO)

HC Wainwright initiated coverage on shares of Phio Pharmaceuticals (NASDAQ:PHIO) in a research note released on Thursday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $14.00 price target on the stock. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.83) EPS and FY2027 earnings at ($0.41) EPS.

Phio Pharmaceuticals Stock Performance

Phio Pharmaceuticals stock opened at $2.96 on Thursday. The firm’s 50-day moving average is $1.92 and its 200-day moving average is $2.01. Phio Pharmaceuticals has a 1 year low of $0.97 and a 1 year high of $9.79. The company has a market cap of $14.20 million, a P/E ratio of -0.27 and a beta of 0.84.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Phio Pharmaceuticals stock. Virtu Financial LLC acquired a new stake in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 40,910 shares of the company’s stock, valued at approximately $74,000. Virtu Financial LLC owned about 0.59% of Phio Pharmaceuticals as of its most recent SEC filing. 57.31% of the stock is currently owned by hedge funds and other institutional investors.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.